Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gentian Diagnostics ASOSL:GENT 71 Cash Ratio is 3.31 as of Jun. 2026, which is 50% below its 10-year median of 6.64. GuruFocus rates OSL:GENT with a GF Score™ of 71/100 and a GF Value™ of kr59.63 (Significantly Undervalued). Among 838 Medical Devices & Instruments companies, Gentian Diagnostics AS ranks better than 79.71% on this metric.
Gentian Diagnostics AS has a Cash Ratio of 3.31. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Gentian Diagnostics AS's Cash Ratio or its related term are showing as below:
OSL:GENT'
s Cash Ratio Range Over the Past 10 Years
Min: 2.62 Med: 6.64 Max: 24.69
Current: 3.31
During the past 13 years, Gentian Diagnostics AS's highest Cash Ratio was 24.69. The lowest was 2.62. And the median was 6.64.
OSL:GENT's Cash Ratio is ranked better than 79.71% of 838
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs OSL:GENT: 3.31
Gentian Diagnostics AS (OSL:GENT) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Gentian Diagnostics AS's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS (OSL:GENT) has a Cash Ratio of 3.31 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Gentian Diagnostics AS and its competitors. This is 50% below median its historical median of 6.64. Over the past decade, Gentian Diagnostics AS's Cash Ratio has ranged from 2.62 to 24.69. According to the industry distribution chart, Gentian Diagnostics AS ranks #170 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 20.3%.
Is Gentian Diagnostics AS's Cash Ratio too high?
Gentian Diagnostics AS's current Cash Ratio of 3.31 is 50% below median its 10-year median of 6.64. Over the past 10 years, this metric has ranged from a low of 2.62 to a high of 24.69. The Medical Devices & Instruments industry median Cash Ratio is 0.97. Gentian Diagnostics AS's value of 3.31 is 241.2% above this industry median. Based on the distribution chart, Gentian Diagnostics AS ranks #170 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Gentian Diagnostics AS has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #170 out of 838 companies for Cash Ratio. This places Gentian Diagnostics AS in the top 20% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.97. Gentian Diagnostics AS's value of 3.31 is 241.2% above this benchmark. Historically, Gentian Diagnostics AS's own Cash Ratio has ranged from 2.62 to 24.69 over the past decade. While the company's 10-year median is 6.64 vs. the industry median of 0.97, Gentian Diagnostics AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current Cash Ratio of 3.31 is 241.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Gentian Diagnostics AS and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current Cash Ratio is 3.31, which is 50% below median its own 10-year median of 6.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Significantly Undervalued. The stock's GF Value™ is kr59.63, compared to a current price of kr38.20 — trading 35.9% below its estimated fair value. The current Cash Ratio is 3.31, which is 50% below median its 10-year median of 6.64 and 241.2% above the Medical Devices & Instruments industry median of 0.97. Gentian Diagnostics AS's overall GF Score™ is 71/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current Cash Ratio is 3.31 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr38.20 is trading 35.9% below its estimated GF Value™ of kr59.63.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for OSL:GENT:
Cash Ratio: 3.31 (50% below median its 10-year median of 6.64)
GF Value™: kr59.63 vs. price of kr38.20 (35.9% below fair value)
Industry Position: 241.2% above the Medical Devices & Instruments median (#170 of 838)
No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
71GF Score
Get the complete analysis for OSL:GENT
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:GENT has been successfully added to your 
